Table 1.
Baseline demographics and characteristics.
| Characteristic | DAPA + MET alone (n = 37) | DAPA + MET + other glucose-lowering drugs (n = 29)a |
Total (n = 66) |
|---|---|---|---|
| Age (years) | 57.1 ± 9.3 | 55.1 ± 8.6 | 56.3 ± 9.0 |
| Female, n (%) | 14 (37.8) | 12 (41.4) | 26 (39.4) |
| Weight (kg) | 91.6 ± 17.9 | 94.6 ± 17.6 | 93.0 ± 17.7 |
| Waist circumference (cm) | 111.0 ± 15.0 | 119.0 ± 16.2∗ | 114.5 ± 15.9 |
| Disease duration (years) | 8.1 ± 5.0 | 11.6 ± 8.5∗ | 9.7 ± 6.9 |
| Systolic BP (mmHg) | 138.6 ± 18.5 | 134.7 ± 14.0 | 136.8 ± 16.6 |
| Diastolic BP (mmHg) | 81.5 ± 9.3 | 81.0 ± 12.6 | 81.3 ± 10.8 |
| HbA1c (%) | 8.8 ± 1.6 | 9.7 ± 1.5 | 9.2 ± 1.6 |
| BMI (kg/m2) | 33.1 ± 6.2 | 33.8 ± 6.3 | 33.4 ± 6.1 |
| Creatinine (μmol/L) | 75.1 ± 17.6 | 76.3 ± 15.5 | 75.6 ± 18.2 |
| Microalbumin (μg/mg) | 119.5 ± 139.6 | 67.1 ± 80.6 | 96.5 ± 118.6 |
| eGFR (mL/min) | 95.9 ± 29.1 | 96.6 ± 24.1 | 95.5 ± 29.7 |
All values are presented as mean ± standard deviation unless otherwise stated. BMI, body mass index; BP, blood pressure; DAPA, dapagliflozin; eGFR, estimated glomerular filtration rate; HbA1c, glycosylated hemoglobin; MET, metformin. aAdditional glucose-lowering agents included glimepiride or insulin. ∗p < 0.05 versus DAPA + MET alone.